Study Finds Calcium Dobesilate Fails to Reduce Incidence of Macular Edema
May 3, 2009
As recently reported on MedPage Today, Christos Haritoglou, M.D., of Ludwig-Maximilians-University in Munich, Germany, and fellow researchers reported in the April 2009 issue of The Lancet, that in a randomized, placebo-controlled trial, calcium dobesilate failed to lower the incidence of clinically significant macular edema. Specifically, over five years of follow-up, the probability of macular edema was 35% in the treatment arm, not significantly different from the 28% seen in the placebo arm.
While the researchers were disappointed by the result, they noted the importance of rejecting the utility of a drug already on the market and thereby stop the costly use of a pharmaceutical that may have limited or no benefit to the patient.
Read the full story on MedPage Today.
You might also enjoy...
- Clinical Trial Finds Erectile Dysfunction Drugs Viagra and Cialis Pose No Threat to Retina
- How Effective Are AMD Drugs in Treating Diabetic Macular Edema?
- FDA Approves Lucentis for Treatment of Retinal Vein Occlusion
- Can Preconditioning Cornea Improves Transplant Success?
- Intravitreous Injections of Pegaptanib (Macugen) May Help Prevent Further Vision Loss From Central Retinal Vein Occlusion
Comments
Jump down to form below to submit your own comments
